MYCOPLASM M 500 Mycophenolate mofetil (500mg) Mycophenolate mofetil is an immunosuppressive medication commonly used to prevent rejection in organ transplant recipients. It is also used in certain autoimmune disorders. Mycophenolate mofetil is a prodrug that is converted to its active form, mycophenolic acid, in the body. Here are key points about mycophenolate mofetil: Indications: Organ Transplantation: MYCOPLASM M 500 is widely used to prevent rejection in individuals who have undergone kidney, heart, or liver transplantation. Autoimmune Disorders: It may be prescribed for certain autoimmune conditions, such as lupus nephritis. Mechanism of Action: MYCOPLASM M 500 inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanosine nucleotides. This inhibition suppresses the proliferation of lymphocytes, particularly T and B lymphocytes, which play a key role in the immune response. Dosage and Administration: The dosage of mycophenolate mofetil can vary based on the type of transplant, patient characteristics, and the overall immunosuppressive regimen. It is usually taken orally, with or without food. Monitoring: Regular monitoring of blood counts, kidney function, and mycophenolate drug levels is typically part of the post-transplant management to ensure efficacy and detect potential side effects. Side Effects: Common side effects may include gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain. There is an increased risk of infections, and a potential association with an increased risk of certain cancers. Pregnancy Considerations: Mycophenolate mofetil has been associated with an increased risk of pregnancy complications and congenital malformations. Women of childbearing age are usually advised to use effective contraception during treatment. Drug Interactions: Mycophenolate mofetil may interact with other medications, and it is important to inform the healthcare provider about all medications, including over-the-counter drugs and supplements, being taken. Duration of Treatment: The duration of mycophenolate mofetil treatment is typically long-term and may continue as long as the individual requires immunosuppression after organ transplantation. It is crucial for individuals to take mycophenolate mofetil exactly as prescribed by their healthcare provider. Any concerns or side effects should be promptly discussed with the transplant team or the managing physician. This information provides a general overview, and specific details about the use of mycophenolate mofetil should be discussed with a healthcare professional. Steris Healthcare Pvt. Ltd. is a Leading Pharmaceutical Company in India. Established in the year of May 2018. We have 750+ Products & 16+ Super Specialty Segments. Every week we have a new product in our portfolio. In Last 4 years we are dealing in Chronic Therapy and in 4 years we grow by 200% Annually, because we deal in high quality medicine. Steris medicine manufactures at WHO-GMP Approved Plants & We have Legal manufacturing contracts with all leading manufacturers of India. Today we have 1000+ Business Franchise Partners in PAN India. Steris's medicine supply in India's Top or Reputed Hospitals, Pharmacy, Government use or Railway use. Grow with a similar pace with the STERIS. Be first to launch like us. For further information please contact: info@sterispharma.com order now: https://www.sterisonline.com/product/mycoplasm-m-500-133669